CMTM3 deficiency induces cardiac hypertrophy by regulating MAPK/ERK signaling

Nakamura, 2018, Mechanisms of physiological and pathological cardiac hypertrophy, Nat. Rev. Cardiol., 15, 387, 10.1038/s41569-018-0007-y Frey, 2003, Cardiac hypertrophy: the good, the bad, and the ugly, Annu. Rev. Physiol., 65, 45, 10.1146/annurev.physiol.65.092101.142243 Heineke, 2006, Regulation of cardiac hypertrophy by intracellular signalling pathways, Nat. Rev. Mol. Cell Biol., 7, 589, 10.1038/nrm1983 Berenji, 2005, Does load-induced ventricular hypertrophy progress to systolic heart failure?, Am. J. Physiol. Heart Circ. Physiol., 289, H8, 10.1152/ajpheart.01303.2004 Pan, 2007, Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin, Nature, 445, 433, 10.1038/nature05476 Bisserier, 2015, Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling, Circulation, 131, 390, 10.1161/CIRCULATIONAHA.114.010686 Ye, 2018, Programmed cell death 5 provides negative feedback on cardiac hypertrophy through the stabilization of sarco/endoplasmic reticulum Ca(2+)-ATPase 2a protein, Hypertension, 72, 889, 10.1161/HYPERTENSIONAHA.118.11357 Mezzadra, 2017, Identification of CMTM6 and CMTM4 as PD-L1 protein regulators, Nature, 549, 106, 10.1038/nature23669 Yuan, 2021, CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway, Cancer Cell Int., 21, 510, 10.1186/s12935-021-02159-5 Fan, 2021, CMTM3 suppresses bone formation and osteogenic differentiation of mesenchymal stem cells through inhibiting Erk1/2 and RUNX2 pathways, Genes Dis, 8, 882, 10.1016/j.gendis.2020.12.003 Yuan, 2017, CMTM3 decreases EGFR expression and EGF-mediated tumorigenicity by promoting Rab5 activity in gastric cancer, Cancer Lett., 386, 77, 10.1016/j.canlet.2016.11.015 Wang, 2009, CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis, Cancer Res., 69, 5194, 10.1158/0008-5472.CAN-08-3694 Chrifi, 2017, CMTM3 (CKLF-Like Marvel transmembrane domain 3) mediates angiogenesis by regulating cell surface availability of VE-cadherin in endothelial adherens junctions, Arterioscler. Thromb. Vasc. Biol., 37, 1098, 10.1161/ATVBAHA.116.308792 Siti, 2021, Parkia speciosa hassk. Empty pod extract alleviates angiotensin II-induced cardiomyocyte hypertrophy in H9c2 cells by modulating the Ang II/ROS/NO Axis and MAPK pathway, Front. Pharmacol., 12, 10.3389/fphar.2021.741623 Luo, 2021, Cooperative binding of ETS2 and NFAT links erk1/2 and calcineurin signaling in the pathogenesis of cardiac hypertrophy, Circulation, 144, 34, 10.1161/CIRCULATIONAHA.120.052384 Su, 2014, CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer, Cancer Sci., 105, 26, 10.1111/cas.12304 Tham, 2015, Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets, Arch. Toxicol., 89, 1401, 10.1007/s00204-015-1477-x Cargnello, 2011, Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases, Microbiol. Mol. Biol. Rev., 75, 50, 10.1128/MMBR.00031-10 Kciuk, 2022, Metastasis and MAPK pathways, Int. J. Mol. Sci., 23, 10.3390/ijms23073847